Oncofid p-b (paclitaxel-hyaluronic acid)

Phase 3

Oncofid p-b (paclitaxel-hyaluronic acid) is one of 58 therapeutic programs targeting Urinary Bladder Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Urinary Bladder CancerActive, not recruiting

Urinary Bladder CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

91 competitors in Urinary Bladder Cancer

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Taxol

Xtandi

Gemzar

Velban

Xylocaine

Zocor

Mitosol

Glucophage

Paraplatin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Active, not recruiting

Urinary Bladder Cancer

NCT05024773

Clinical

Trials by Indication[1]

Urinary Bladder Cancer1 trial

A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)

Active, not recruiting·FFidia Farmaceutici s.p.a.·Phase 3·NCT05024773·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oncofid p-b (paclitaxel-hyaluronic acid). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Oncofid p-b (paclitaxel-hyaluronic acid). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fidia Farmaceutici s.p.a. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: FFidia Farmaceutici s.p.a.

Oncofid p-b (paclitaxel-hyaluronic acid)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Urinary Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News